Cargando…
KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients...
Autores principales: | Lohinai, Zoltan, Klikovits, Thomas, Moldvay, Judit, Ostoros, Gyula, Raso, Erzsebet, Timar, Jozsef, Fabian, Katalin, Kovalszky, Ilona, Kenessey, István, Aigner, Clemens, Renyi-Vamos, Ferenc, Klepetko, Walter, Dome, Balazs, Hegedus, Balazs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209707/ https://www.ncbi.nlm.nih.gov/pubmed/28051122 http://dx.doi.org/10.1038/srep39721 |
Ejemplares similares
-
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
por: Ghimessy, Áron Kristof, et al.
Publicado: (2019) -
The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021) -
Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020) -
From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2016) -
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
por: Kenessey, István, et al.
Publicado: (2016)